Neurodevelopmental Disorders - Exposure Details | CTD
Skip navigation

Disease Neurodevelopmental Disorders

These are exposure details associated with the disease and all of its children.



1–50 of 1,121 results.
  Reference Exposure Stressor Number of Receptors Receptors Receptor Notes Medium Exposure Marker Marker Level Measurement Statistic Assay Notes Country Outcome Relationship Disease Phenotype
1. Kalkbrenner AE, et al. (2018). 1,4-dioxane 2,017 Subjects with disease:Autism Spectrum Disorder 1,540 cases and 477 controls United States positive correlation Autism Spectrum Disorder
2. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 21 Controls for disease:Developmental Disabilities Typically Developing serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 0.02 nanograms per gram mean United States
3. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 24 Subjects with disease:Developmental Disabilities serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 1.58 nanograms per gram lipid 25th percentile United States
4. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 49 Subjects with disease:Autism Spectrum Disorder serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 0.01 nanograms per gram 25th percentile United States
5. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 49 Subjects with disease:Autism Spectrum Disorder serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 0.01 nanograms per gram 75th percentile United States
6. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 21 Controls for disease:Developmental Disabilities Typically Developing serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 2.67 picomoles per gram lipid 75th percentile United States
7. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 24 Subjects with disease:Developmental Disabilities serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 0.02 nanograms per gram 95th percentile United States
8. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 21 Controls for disease:Developmental Disabilities Typically Developing serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 2.67 nanograms per gram lipid 75th percentile United States
9. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 49 Subjects with disease:Autism Spectrum Disorder serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 0.01 nanograms per gram mean United States
10. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 49 Subjects with disease:Autism Spectrum Disorder serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 2.8 picomoles per gram lipid 75th percentile United States
11. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 24 Subjects with disease:Developmental Disabilities serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 1.9 nanograms per gram lipid median United States
12. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 24 Subjects with disease:Developmental Disabilities serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 2.04 nanograms per gram lipid mean United States
13. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 21 Controls for disease:Developmental Disabilities Typically Developing serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 1.17 picomoles per gram lipid 5th percentile United States
14. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 21 Controls for disease:Developmental Disabilities Typically Developing serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 3.2 picomoles per gram lipid mean United States
15. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 49 Subjects with disease:Autism Spectrum Disorder serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 2.15 picomoles per gram lipid median United States
16. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 21 Controls for disease:Developmental Disabilities Typically Developing serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 7.2 picomoles per gram lipid 95th percentile United States
17. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 49 Subjects with disease:Autism Spectrum Disorder serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 0.01 nanograms per gram 5th percentile United States
18. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 21 Controls for disease:Developmental Disabilities Typically Developing serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 1.37 picomoles per gram lipid 25th percentile United States
19. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 21 Controls for disease:Developmental Disabilities Typically Developing serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 1.37 nanograms per gram lipid 25th percentile United States
20. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 24 Subjects with disease:Developmental Disabilities serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 2.22 picomoles per gram lipid 75th percentile United States
21. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 21 Controls for disease:Developmental Disabilities Typically Developing serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 0.01 nanograms per gram median United States
22. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 49 Subjects with disease:Autism Spectrum Disorder serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 2.15 nanograms per gram lipid median United States
23. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 24 Subjects with disease:Developmental Disabilities serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 0.27 nanograms per gram lipid 5th percentile United States
24. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 24 Subjects with disease:Developmental Disabilities serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 2.04 picomoles per gram lipid mean United States
25. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 24 Subjects with disease:Developmental Disabilities serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 0.01 nanograms per gram 75th percentile United States
26. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 21 Controls for disease:Developmental Disabilities Typically Developing serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 0.01 nanograms per gram 5th percentile United States
27. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 21 Controls for disease:Developmental Disabilities Typically Developing serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 1.17 nanograms per gram lipid 5th percentile United States
28. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 24 Subjects with disease:Developmental Disabilities serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 0.01 nanograms per gram median United States
29. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 49 Subjects with disease:Autism Spectrum Disorder serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 1.15 nanograms per gram lipid 5th percentile United States
30. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 21 Controls for disease:Developmental Disabilities Typically Developing serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 7.2 nanograms per gram lipid 95th percentile United States
31. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 24 Subjects with disease:Developmental Disabilities serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 1.9 picomoles per gram lipid median United States
32. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 21 Controls for disease:Developmental Disabilities Typically Developing serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 0.04 nanograms per gram 95th percentile United States
33. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 24 Subjects with disease:Developmental Disabilities serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 3.39 nanograms per gram lipid 95th percentile United States
34. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 24 Subjects with disease:Developmental Disabilities serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 0.27 picomoles per gram lipid 5th percentile United States
35. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 21 Controls for disease:Developmental Disabilities Typically Developing serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 3.2 nanograms per gram lipid mean United States
36. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 49 Subjects with disease:Autism Spectrum Disorder serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 0.01 nanograms per gram median United States
37. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 49 Subjects with disease:Autism Spectrum Disorder serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 2.66 picomoles per gram lipid mean United States
38. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 21 Controls for disease:Developmental Disabilities Typically Developing serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 2.12 nanograms per gram lipid median United States
39. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 24 Subjects with disease:Developmental Disabilities serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 0.01 nanograms per gram mean United States
40. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 24 Subjects with disease:Developmental Disabilities serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 0.01 nanograms per gram 25th percentile United States
41. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 21 Controls for disease:Developmental Disabilities Typically Developing serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 0.01 nanograms per gram 25th percentile United States
42. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 24 Subjects with disease:Developmental Disabilities serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 1.58 picomoles per gram lipid 25th percentile United States
43. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 49 Subjects with disease:Autism Spectrum Disorder serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 1.15 picomoles per gram lipid 5th percentile United States
44. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 24 Subjects with disease:Developmental Disabilities serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 3.39 picomoles per gram lipid 95th percentile United States
45. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 24 Subjects with disease:Developmental Disabilities serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 0 nanograms per gram 5th percentile United States
46. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 21 Controls for disease:Developmental Disabilities Typically Developing serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 2.12 picomoles per gram lipid median United States
47. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 49 Subjects with disease:Autism Spectrum Disorder serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 6.99 picomoles per gram lipid 95th percentile United States
48. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 49 Subjects with disease:Autism Spectrum Disorder serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 1.71 nanograms per gram lipid 25th percentile United States
49. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 49 Subjects with disease:Autism Spectrum Disorder serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 2.8 nanograms per gram lipid 75th percentile United States
50. Hertz-Picciotto I, et al. (2011). 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 21 Controls for disease:Developmental Disabilities Typically Developing serum 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 0.01 nanograms per gram 75th percentile United States
1–50 of 1,121 results.